San Mateo, United States
AusperBio, founded in 2019, is a clinical-stage biopharmaceutical company with dual operations in the USA and China. Guided by its ambitious slogan, "Transforming Patient Lives For a Better Tomorrow," the company focuses on advancing oligonucleotide and targeted delivery technologies to offer transformative therapies, particularly against chronic hepatitis B.
Central to AusperBio's innovation is its proprietary Med-OligoTM ASO platform, which introduces novel insights into antisense oligonucleotide (ASO) design. This platform aims to enhance ASO therapeutics by employing efficient targeted delivery conjugation technologies, thereby expanding treatment applications to a wide range of viral infections, metabolic conditions, genetic disorders, and immune diseases.
The recent injection of $63.00M in a Series B funding round on 01 September 2025 highlights the strong investor confidence in AusperBio's potential. Key investors, including Qiming Venture Partners, Sherpa Capital, CDH Investments, Genesis Capital, YuanBio Venture Capital, and Hankang Capital, underscore the company's promising trajectory in the Biopharma, Biotechnology, and Pharmaceutical industries.
